The autotaxin α splice variant (ATXα) contains a unique polybasic insertion of unknown function. Results: ATXα binds strongly to heparin and cellassociated heparan sulfate.
SUMMARY
Autotaxin (ATX) is a secreted lysophospholipase D that generates the lipid mediator lysophosphatidic acid (LPA), playing a key role in diverse physiological and pathological processes. ATX exists in distinct splice variants, but isoform-specific functions remain elusive. Here we characterize the ATXα isoform, which differs from the canonical form (ATXβ) in having a 52-residue polybasic insertion of unknown function in the catalytic domain. We find that the ATXα insertion is susceptible to cleavage by extracellular furin-like endoproteases, but cleaved ATXα remains structurally and functionally intact due to strong interactions within the catalytic domain. Through ELISA and surface plasmon resonance assays, we show that ATXα binds specifically to heparin with high affinity (K d ~10 -8 M), whereas ATXβ does not; furthermore, heparin moderately enhanced the lysophospholipase D activity of ATXα. We further show that ATXα, but not ATXβ, binds abundantly to SKOV3 carcinoma cells. ATXα binding was abolished after treating the cells with heparinase III, but not after chondroitinase treatment. Thus, the ATXα insertion constitutes a cleavable heparin-binding domain that mediates interaction with heparan sulfate proteoglycans, thereby targeting LPA production to the plasma membrane. __________________________________________ Autotaxin (ATX or NPP2 ) is a secreted ectonucleotide pyrophosphatase/phosphodiester-ase (NPP) that functions as a lysophospholipase D (lysoPLD), converting lysophosphatidyl-choline (LPC) into the lipid mediator lysophosphatidic acid (LPA) (1-3). LPA, a major serum constituent, signals through specific G protein-coupled receptors to influence numerous cellular processes including cell migration, proliferation and differentiation (3;4) . ATX and LPA signaling play a vital role in embryonic development (5;6) and are implicated in a wide variety of physiological and pathological processes, as diverse as lymphocyte homing (7;8) , neurogenesis (9;10), tumor progression (11;12) and fibrosis (13) . Full-length ATX is synthesized as a preproenzyme. Upon removal of its N-terminal signal peptide followed by N-glycosylation, ATX is further processed by proprotein convertases and secreted via the classical secretory pathway as an active glycoprotein of 110-120 kDa (14;15) . Mature ATX consists of a central phosphodiesterase domain (PDE) flanked by two N-terminal somatomedin Blike (SMB) domains and a C-terminal nuclease-like (NUC) domain. Structural studies have revealed that the PDE domain contains a deep lipid-binding pocket at the active site and a nearby open tunnel that might function as a product release channel (16;17) . The NUC domain serves to maintain the rigidity of the PDE domain, while the N-terminal SMB domains mediate binding of ATX to activated integrins (16;18) . Integrin binding localizes ATX to the plasma membrane, thus providing a mechanism to generate LPA in the vicinity of its cognate receptors (18;19) . Whether ATX uses additional or alternative mechanisms for spatially and temporally restricted LPA production is unknown.
The intricacy of the ATX-LPA receptor system is further enhanced by alternative splicing of ATX mRNA, giving rise to distinct isoforms (3;20;21) . However, isoform-specific functions of ATX are still largely uncharacterized. The canonical isoform, termed ATXβ, was originally cloned from teratocarcinoma cells (3;22) and later found to be identical to plasma lysoPLD, accounting for LPA production in the circulation (1;2) . Virtually all our current understanding of ATX is derived from studies on ATXβ. A longer isoform, ATXα, was originally isolated as an 'autocrine motility factor' from melanoma cells (23) and is characterized by a unique 52-residue polybasic insertion of unknown function in the catalytic domain (3;24) . Conceivably, the ATXα insertion could confer different catalytic activity, cellular localization, processing or binding partner preference. On the other hand, it was reported that the insertion renders ATXα intrinsically unstable and prone to proteolyic degradation, which would be a mechanism to rapidly terminate ATXα activity in vivo (20;21) .
In the present study, we explore the unique properties of ATXα compared to those of ATXβ, guided by the polybasic nature of the ATXα insertion and by the crystal structure of ATXβ. We show that the ATXα insertion constitutes a heparin-binding domain that mediates specific interaction with cell-surface heparan sulfate (HS) proteoglycans. As such, the insertion functions to direct ATXα to the plasma membrane thereby ensuring localized LPA production and signaling. We also show that the insertion is susceptible to processing by (an) extracellular furin-like proprotein convertase(s), which might serve to fine-tune the binding of ATXα to cell-surface HS proteoglycans. ATX Constructs and Recombinant Protein -For ATX overexpression studies, human ATXβ was ligated in the pcDNA3 vector with a 3' Myc tag, as previously described (26) . Human ATXα, ligated in pcDNA3 containing a 3' Myc/His tag was a generous gift from Dr. Andree Blaukat (MerckSerono, Darmstadt, Germany). Mutant ATXα(R340A) was generated using the Stratagene site-directed mutagenesis kit, with the following primers:
EXPERIMENTAL PROCEDURES
p686-forward: GGCTAAGAGACCTAAGGCGAAAGTTGCCCC, and p687-reverse: GGGGCAACTTTCGCCTTAGGTCTCTTAGCC). For production of recombinant protein, ATXα and ATXβ were ligated in pcDNA5-FRT (Invitrogen) with a C-terminal Myc-tag and a 6xHis-tag. HEK293 cells stably expressing ATXα or ATXβ were generated using the FLPin system (Invitrogen). Recombinant His-tagged ATX was purified from conditioned HEK293 medium using POROS-20 MC columns pre-loaded with Ni 2+ , as previously described (27) . The column was washed with eight to ten column volumes of buffer A (20 mM Tris-HCl pH 8.0, 150 mM NaCl and 20 mM imidazole). ATX protein was eluted with a linear gradient of buffer A containing 750 mM imidazole.
Expression Analysis -Cells were grown to confluency and total RNA was extracted using the RNeasy mini kit and column DNase treatment (Qiagen). First strand cDNA synthesis was performed using 2 ug total RNA, 0.5 ug oligo-dT primers (Promega), 500 nM dNTPs (Roche), 40 units RNAsin (Promega), 10 mM DTT (Invitrogen) and 200 units Superscript II RT. Quantitative ATX expression was measured using the TaqMan gene expression probe Hs00196470_m1 in an ABI 7500 Fast Sequence Detection System (Applied Biosystems). Cycling parameters were: 10 min. at 95°C followed by 40 cycles of 15 sec. at 95°C and 1 min. at 60°C. The relative product levels were quantified using the ddCt method and were normalized to GAPDH expression. Expression of the ATXα and ATX β isoforms was measured by RT-PCR using primers (forward 5'-ATTACAGCCACCAAGCAAGG-3' and reverse 5'-TCCCTCAGAGGATTTGTCAT-'3) located around the insertionion of the ATXα-specific insertion, resulting in a 209 bp fragment for ATXα and a 366 bp fragment for ATX β. Human plasmid DNA was used to confirm the specificity of the primers, which were species-independent.
Transfection and Western Blotting -HEK293 cells were transfected with ATX constructs using the calcium phosphate method. At 24 hrs after transfection, cells were incubated in serum-free DMEM for 48 hrs. Conditioned medium was centrifuged (5000 rpm for 30 min.) to remove cell debris. Samples were analyzed by gel electrophoresis using NuPAGE 4-12% Bis-Tris gels (Invitrogen) under either reducing or non-reducing conditions. For Western blot analysis, nitrocellulose filters were blocked using 5% non-fat powdered milk and probed with primary antibodies, followed by HRP-conjugated secondary antibodies (Dako, Glostrup, Denmark) and proteins were visualized using ECL detection (Amersham, Arlington Heights, IL).
Cell Migration -Chemotactic migration of human A2058 melanoma cells was measured in 48-wells Boyden chambers (Neuroprobe) as described previously (28) . Filters (8 µm pores) were coated with gelatin and cells were serum starved overnight, trypsinized and seeded in the upper chamber. ATX (2 ng/ml) was added to the bottom chamber in the presence of 2 µM LPC(18:1) and 1 mg/ml fatty acidfree BSA. After 4 hrs, cells at the top side were removed and migrated cells at the bottom side of the filter were fixed, stained and quantified.
Immunofluorescence-HEK293 cells were transfected with C-terminally Myc-tagged ATXα or ΑΤΧβ. At 24 hrs after transfection, cells were fixed with icecold ethanol and ATX was visualized by confocal microscopy using anti-Myc antibody (9E10) and anti-mouse Alexa488.
ATX Activity Assays -To measure lysoPLD activity, LPC(18:1) was used as substrate in 50 mM Tris (pH 7.4), 0.01% Triton X-100, 25 mM CaCl 2 , containing 2.5 mM homovanillic acid, 2 units ml -1 horseradish peroxidase, 2 units/ml choline oxidase, essentially as described (29) . After addition of recombinant ATX, the increase in fluorescence was monitored at 37°C (excitation/emission: 355/460 nm) as described (26;29) . Nucleotide phosphodiesterase activity was measured using pNP-TMP (Sigma-Aldrich) as substrate in 50 mM Tris (pH 7.8), 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 1 mg ml -1 fatty-acid free BSA. After addition of recombinant ATX, the amount of liberated para-nitrophenolate (pNP) was determined by the absorbance at 405 nm, as described (26) . Michaelis-Menten kinetic parameters were determined using GraphPad Prism software.
ELISA -Binding of ATX (α or β) to heparin was evaluated by ELISA in two ways: first, application of ATX to heparin-coated wells of microtiter plates; and second, competition assays in which ATX was first incubated with heparin and then transferred to a heparin-coated plate. A 96-well flat-bottom plate was incubated for 16 h with 100 µl of 10 µg ml -1 heparin in coating buffer. As a control, wells were coated for 16 h with 1 μg ml -1 ATX in 0.05 M carbonate-bicarbonate buffer (Sigma-Aldrich, St Louis, MO). After blocking with PBS containing 2% BSA (w/v) for 1 h, 1 μg ml -1 ATX (in PBS containing 2% BSA) was added and incubated for 2 hrs. Plates were washed six times with PBS and bound ATX was detected using goat anti-ATX IgG (1:200; R&D systems), followed by incubation with alkaline phosphatase-conjugated rabbit anti-goat IgG (1:2000; Sigma-Aldrich), both for 1 hr. Plates were washed six times with PBS, and enzyme activity was detected using 100 μl of a p-nitrophenyl phosphate solution (1 mg ml -1 ) containing 1 M diethanolamine and 0.5 mM MgCl 2 (pH 9.8). Absorbance was measured at 405 nm. For the competition assay, 0.1 μg ml -1 ATX was incubated with an increasing content of heparin (0-1 mg ml -1 ) for 1 h in 100 μl and transferred to a 96-well plate previously coated with heparin. Plates were washed six times with PBS before measuring bound ATX, as described above.
Surface Plasmon Resonance assays -ATX binding to heparin was measured by surface plasmon resonance spectroscopy using a Biacore T100 machine (Biacore, GE Healthcare). Recombinant ATXα and ΑΤΧβ were covalently coupled to separate flow cells of a CM5 sensor chip at pH 4.0 at roughly equal amounts (about 10,000 response units). Increasing concentration of unfractionated heparin in running buffer (150 mM NaCl, 20 mM Hepes pH 7.6) were injected across the chip at flow rate of 50 µl/min. Injection of 1 M NaCl was used to regenerate the chip surface at the end of each cycle. The response units (RUs) for the binding of heparin were evaluated after subtraction of the signal in a flow cell of the same sensor chip which has been left uncoated. To determine the apparent dissociation constant ( K d ), the background-subtracted data were fit using a model in which the total binding results from specific binding plus a linear nonspecific component and a concentration-independent background according to the equation:
where c is the protein concentration, . Bound ATX was detected by a goat anti-ATX IgG antibody (1:50; R&D systems) and an Alexa488 fluorochrome conjugated anti-goat IgG antibody (1:100; Invitrogen). To determine heparan sulfate or chondroitin/dermatan sulfate dependency, cells were predigested with 20 mIU heparinase III or 100 mIU chondroitinase ABC, respectively, ml -1 basal culture medium containing 1% FCS for 2 h at 4°C. Omission of the first antibody was used as a negative control. Flow cytometry analyses were performed using a Beckton Dickinson FACSscan or FACScalibur. Viable cells were gated using forward and side scatter, and the fluorescence of this population was measured.
RESULTS AND DISCUSSION

ATXα: Structure and Expression
The mammalian ATX gene is organized in 27 exons. The three best known splice variants of ATX, termed α, β and γ, differ by the presence or absence of sequences encoded by exons 12 and 21 (Fig. 1A) . ATXα contains an exon 12-encoded region of 52 residues in the PDE domain. The canonical ATXβ isoform lacks exons 12 and 21, while the 'brainspecific' ATXγ isoform (formerly PD-1α) contains an 25-aa insertion encoded by exon 21 in the NUC domain (30;31) . A recently identified fourth isoform, termed ATXδ, is identical to ATXβ except for a four-residue deletion in the region that links the NUC and PDE domain (not illustrated) (21) .
Here we explore the properties of ATXα relative to those of ATXβ. The 52-aa insertion in ATXα is highly basic with a calculated pI~11.5. Sequence inspection revealed a consensus cleavage site for furin and furin-like endoproteases (target sequence R-x-K/R-R; ref. (32) ) between residues R340 and K341 (Fig. 1B) . Cleavage of ATXα at R340 by (an) unidentified protease(s) was observed in a previous study (20) . Furthermore, we noticed by guest on July 11, 2017 http://www.jbc.org/ Downloaded from that the insertion contains putative heparin-binding motifs, which are commonly characterized by clusters of basic residues (Fig. 1B, indicated in blue) . The crystal structure of ATXβ (refs. (16;17) ) allowed us to understand the localization of the insertion in ATXα. The insertion is predicted to be unstructured and solvent exposed, starting right before an α-helix in the PDE domain (α-helix no. 10; ref. (16)). In Fig.1C , it is depicted as a flexible, hydrophilic loop that protrudes out of the PDE domain, pointing away from the catalytic site and the substrate binding pocket. However, we cannot rule out the possibility that the insertion adopts a more ordered conformation and might interact with the ATX surface. Given its location and hydrophilic nature, the insertion loop is unlikely to affect the tertiary structure of the ATXα catalytic domain.
We examined ATX expression in various tissues and cell lines. In agreement with previous studies (7;20;33) and publicly available expression data (34), highest ATX mRNA expression (all isoforms) was found in brain, kidney, spleen and lung, and somewhat lower expression in liver, skin and adipose tissue ( Fig. 2A) . ATXα mRNA has been detected in kidney and liver (20) as well as in melanoma (23) and non-small-cell lung cancer cells (35) , but otherwise ATXα is much less widely expressed than ATXβ. We detected ATXα mRNA in human skin fibroblasts (HF cells) and glioblastoma cells (SNB-78 and U-138) as well as in mouse skin (Fig. 2B) , presumably reflecting expression in dermal fibroblasts since skin-derived keratinocytes lacked detectable ATXα (data not shown). ATXα-specific antibodies raised against sequences in the insertion recognized overexpressed ATXα in HEK293 cells, but unfortunately they failed to detect endogenous ATXα in selected cell lines (LvM, unpublished results). It is of note that ATXα was consistently found co-expressed with ATXβ in the cell lines and tissues examined (Fig. 2B) . We therefore examined whether both isoforms might interact, but coimmunoprecipitation studies using transfected HEK293 cells did not support this possibility (data not shown). In transfected cells, ATXα and ATXβ showed a similar localization pattern in intracellular vesicles, consistent with both isoforms following the classical trafficking route prior to secretion (Fig.  2C) .
Furin-Mediated Cleavage of the Insertion at R340
It was previously reported that the insertion renders ATXα unstable and prone to proteolyic degradation in vivo (20;21) . We examined the expression of both ATXα and ATXβ in HEK293 cells under reducing and non-reducing conditions. When analyzed by reducing SDS-PAGE, secreted ATXα was consistently detected not only as a ~120 kDa protein but also as two cleavage fragments of ~70 kDa and ~40 kDa, as shown by using antibodies against the C-and N-terminal parts, respectively (Fig. 3A) . In contrast, ATXβ was always detected as the fulllength protein (Fig. 3A) . This result is consistent with secreted ATXα being cleaved at the furin consensus site (R340). Indeed, mutant ATXα(R340A) was resistant to proteolysis while treatment of ATXα−expressing cells with a specific inhibitor of furin and furin-like endoproteases (decanoyl-Arg-Val-Lys-Arg-chloromethylketone (36)) prevented proteolysis. Furthermore, addition of recombinant furin caused a nearly complete cleavage of full-length ATXα, but left ATXα(R340A) and ATXβ intact (Fig. 3A) . Importantly, ATXα cleavage was detected only in the medium but not in cell lysates (Fig. 3A) , indicating that proteolytic processing occurs extracellularly rather than along the intracellular trafficking route. Although furin and furin-like proprotein convertases predominantly reside in the trans-Golgi network, they can also traffic to the cell surface and be shed or secreted into the extracellular milieu (37;38). In particular, furin and its relatives PC5 and PACE4 are known to secreted and to process diverse extracellular substrates, including growth factors, receptors and metalloproteinases (37) (38) (39) (40) . Which of the secreted furin family members may preferentially attack the ATXα insertion remains to be determined.
As shown in Fig. 3B , ATXα fragmentation was not observed under non-reducing conditions (Fig. 3B) . Thus, furin-mediated cleavage at R340 leaves ATXα fully intact. As can be inferred from the structure (Fig. 3C ), cleavage at R340 leaves the N-and C-terminal parts tightly together due to an extended interaction surface area between both parts (10,980 Ǻ 2 ; as calculated by PISA (41)). The stability of the interface is primarily due to van der Waals interactions and numerous hydrogen bonds, as revealed by FoldX analysis (42) . Stability is further reinforced by ionic interactions and a disulfide linkage between Cys157and Cys403 (Fig. 3C) . It thus appear that the N-an C-terminal parts of cleaved ATXα form a very stable structure (calculated free energy of dissociation >100 kcal mol -1 ) that can only be separated under reducing by guest on July 11, 2017 http://www.jbc.org/ Downloaded from SDS-PAGE conditions. These results refute previous notions that the ATXα isoform is unstable and rapidly degraded in vivo (20;21) .
ATX Catalysis
We examined the kinetic parameters of ATXα versus ATXβ, using LPA(18:1) and pNP-TMP as substrates. As shown in Fig. 4A , the catalytic efficiency (Vmax/Km) of ATXα towards LPC was about 70% of that of ATXβ, due to a lower Vmax value (Fig. 4A) . Treatment of ATXα with recombinant furin (to fully cleave the insertion) did not affect lysoPLD activity (Fig. 4B) . Moreover, ATXα and ATXβ (at 2 nM) were equally effective in stimulating the transwell migration of A2058 melanoma cells in the presence of 2 µM LPC during a 4-hrs time period (Fig. 4C) . From these results, we conclude that ATXα and ATXβ show roughly similar LPC-hydrolyzing efficiency, regardless of the cleavage state of ATXα.
However, the catalytic efficiency of ATXα towards pNP-TMP was about 5-fold lower than that of ATXβ due to a much lower Vmax (Fig. 5A) . We have currently no structural data that can explain this observation. LPA inhibited pNP-TMP hydrolysis by ATXα and ATXβ with K i values of 50 nM and 110 nM, respectively), suggesting that the insertion may exert a moderately positive effect on LPA binding affinity ( Fig. 5B; cf. (26) . Finally, both isoforms were equally sensitive to the ATX inhibitor HA130 (ref. (29) ; data not shown).
ATXα Binds Specifically to Heparin
The positively charged K/R clusters in the ATXα insertion (Fig. 1B) could confer binding to heparin, possibly in a cooperative manner (43;44) . Heparin is structurally very similar to heparan sulfate (HS), which is ubiquitously expressed as proteoglycans on cell surfaces and in extracellular matrices, where it recruits growth factors, chemokines and other molecules to fine-tune signaling events under both physiological and pathophysiological conditions (45) (46) (47) . High-affinity binding of ATX to heparin in vitro could point to an HS-mediated mechanism for localized LPA production in vivo.
We first determined the binding of ATXα and ATXβ to unfractionated heparin (from intestinal mucosa) using ELISA, in which recombinant ATX was added to heparin-coated wells. We found that ATXα binds strongly to immobilized heparin, whereas ATXβ hardly did (Fig. 6A) . As a control for specificity, both isoforms were immobilized directly to the wells (without prior heparin coating), which gave similar readings for both isoforms (Fig. 6A) . In addition, we used a competition ELISA, in which ATX was pre-incubated with various amounts of soluble heparin prior to addition to heparin-coated wells. We observed a dose-dependent inhibition of ATXα binding to immobilized heparin (IC 50 ~ 4.5 µg/ml or 300 nM), confirming that the observed ATXα-heparin interaction is specific (Fig. 6B) .
We next examined ATX-heparin binding using surface plasmon resonance, in which recombinant ATX was immobilized and heparin was used as the analyte. Again, we found that ATXα binds heparin much stronger than does ATXβ (Fig. 7A-C) . As shown in Fig. 7A , heparin binds to ATXα rapidly and dissociates slowly, consistent with specific binding. In contrast, ATXβ showed very fast heparin binding and dissociation kinetics (Fig. 7B) , suggestive of non-specific binding dominated by electrostatic interactions. On the basis of an average MW of heparin of 15 kDa, we determined the apparent K d of ATXα for heparin to be approx. 10 nM. The K d of ATXβ could not reliably be determined since heparin binding did not reach a plateau; however, it is at least 10-fold lower than that of ATXα (Fig. 7C) . We conclude that the insertion of ATXα confers stable, high-affinity binding to heparin with a slow dissociation rate.
An electrostatic surface charge representation of ATX sheds some light on how and where heparin may bind (Fig. 7D) . The model shows several positively charged patches common to both isoforms. It is seen that the basic insertion of ATXα is located close to one of those patches in the catalytic domain (Fig. 7D) , suggesting that the insertion and the positively charged surface patch might act in a cooperative manner to enhance binding to heparin/HS. Co-crystallization studies using defined heparin/HS fragments should help to test this scenario and, furthermore, uncover to what extent proteolytic cleavage at R340 may affect heparin binding.
We also tested whether heparin may affect the catalytic activity ATXα. As shown in Fig. 8 , heparin enhanced the lysoPLD activity of ATXα towards LPC(18:1) up to two-fold in a concentrationdependent manner (EC 50 ~100 nM). In contrast, heparin had little or no effect on the activity of ATXβ (Fig. 8) .
ATXα Binds to Cell-Surface HS Proteoglycans
The observed high-affinity binding of ATXα to heparin strongly suggests that this isoform preferentially interacts with HS proteoglycans, as a means to target LPA production to the cell surface. Although heparin and HS are structurally similar, HS is less negatively charged and shows more structural hetereogeneity compared to heparin. We measured the binding of both ATXα and ATXβ to SKOV3 ovarian carcinoma cells, which have a wellcharacterized glycosaminoglycan expression pattern (48) (49) (50) . Flow cytometry analysis shows that ATXα binds abundantly to the cell surface of SKOV3 cells, whereas ATXβ does not (Fig. 9A, B) . Cell binding was strictly dependent on HS, since pretreatment of the cells with the HS-degrading enzyme heparinase III almost completely abolished ATXα binding. Binding was HS-specific in that digestion of cellassociated chondroitin/dermatan sulfate, another class of highly sulfated glycosaminoglycans, did not affect ATXα binding (Fig. 9) . Since heparin stimulates ATXα activity in vitro (Fig. 8) , binding of ATXα to HS proteoglycans may serve not only to target LPA production to the plasma membrane, but also to locally increase the catalytic efficiency of this particular isoform.
In conclusion, our study is the first to define an isoform-specific function for ATX. The polybasic insertion of ATXα constitutes a heparin-binding domain that targets ATX activity to the plasma membrane via binding to cell-surface HS proteoglycans. Previous studies have established that ATX binds to activated integrins via its N-terminal SMB domains, which provides one mechanism for localized production of LPA close to its cognate receptors (16;18) . Binding of ATXα to cell-surface HS proteoglycans via it unique polybasic insertion represents an additional, isoform-specifc mechanism for spatially and temporally restricted LPA production (19) . Future studies should explore to what extent furin-mediated cleavage of the insertion may modulate its heparin/HS-binding properties, either positively or negatively, and assess whether ATXα, HS and a furin-like protease can be detected in a ternary complex at the cell surface.
interface between the two cleavage fragments. The polybasic insertion of ATXα protrudes into the direction of the viewing plane, depicted by its first and last amino acid (aa 325 and 376, respectively). 
